Following over a year of slow uptake, Vertex Pharmaceuticals and CRISPR Therapeutics expect Casgevy revenues to nearly triple ...
In early February 2026, WuXi Biologics announced a license and research service agreement granting Vertex Pharmaceuticals ...
The next 12 months will be important for the drugmaker.
On Monday, Goldman Sachs reaffirmed a Buy rating on shares of Vertex Pharmaceuticals (NASDAQ:VRTX) Incorporated (NASDAQ:VRTX), with a set price target of $598.00. At a recent event, Vertex presented ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results